CTXR
Citius Pharmaceuticals Inc. CommonstockNASDAQ
citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.48 | 2026-11-11 | +6.32% | 4.843 |
| 1M | 0.43 | 2026-10-19 | +19.44% | 0.209 |
| 3M | 0.57 | 2026-08-18 | -10.64% | 0.564 |
| 6M | 0.53 | 2026-05-18 | -3.05% | 1.205 |
| 1Y | 1.07 | 2025-11-18 | -52.25% | 1.992 |
| 2Y | 5.61 | 2024-11-18 | -90.88% | — |
| 5Y | 42.25 | 2021-11-18 | -98.79% | 1.110 |
Citius Pharmaceuticals Inc. Common (NASDAQ:CTXR) stock price today is $0.51, and today's volume is 68,049. CTXR is down 1.513% today. The 30 day average volume is 264,964. CTXR market cap is $14.03M with 27.45M shares outstanding.
